Effectiveness of Different Fibrinogen Preparations in Restoring Clot Firmness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-20

Study Completion Date

2024-02-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fibrinogen concentrate is produced by different manufacturers using different purification technologies. The products available in Italy are three: RiaSTAP (CSL Behring), FIBRYGA (Octapharma), and FibCLOT (LFB). RiaSTAP and FIBRYGA are sold in 1-gram vials, and FibCLOT - in 1.5-gram vials. A recent in vitro study assessed how these products affected the clot firmness measured by the ROTEM FIBTEM maximum clot firmness (MCF) parameter. In vitro conditions, FibCLOT was verified to be the most efficient in increasing clot firmness.

The present study is aimed to assess, in a series of patients undergoing cardiac surgery with cardiopulmonary bypass, the hypothesis that the FibCLOT fibrinogen is superior to the RiaSTAP fibrinogen in increasing the FIBTEM MCF parameter in a clinical model of bleeding (postoperative bleeding after complex cardiac surgery).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

NCT01575756

Congenital Fibrinogen Deficiency Afibrinogenemia

COMPLETED PHASE2

Use of Fibryga, a Fibrinogen Concentrate in Real World: Retrospective Collection of Clinical Data

NCT04106895

Bleeding

COMPLETED

U.S. Study of Fibrocaps in Surgical Hemostasis

NCT01256164

Postoperative Hemorrhage

COMPLETED NA

A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)

NCT02528708

Postpartum Hemorrhage

WITHDRAWN PHASE1/PHASE2

Human Fibrinogen - Pharmacokinetics

NCT00496262

Fibrinogen Deficiency

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Effectiveness of DIfferent fibrinogen PreparatiOns in Restoring clot firmness (EDIPO RE) is a pragmatic, double-blinded, randomized controlled trial testing the hypothesis that FibCLOT is superior to RiaSTAP in restoring fibrinogen-dependent clot firmness in cardiac surgery acquired hypofibrinogenemia.

A randomization sequence was generated by a computerized system, and then sealed envelopes containing the drug assigned were prepared. The randomization ratio of the treatment arms was 1:1. An unblinded biologist was in charge of running the ROTEM® tests, randomization, drug preparation, and masking, and its delivery to the operating room. The attending anesthesiologist, the surgical staff, and the medical staff in the ICU and ward were blinded.

After protamine administration, if microvascular bleeding was observed or suspected, POC testing, including ROTEM® EXTEM and FIBTEM, was run. If FIBTEM MCF was lower than 10 mm, the patient was randomly allocated to receive a dose of RiaSTAP® or FibCLOT® of 30 mg/kg, approximated to the closest between 2 or 3 grams. If no sign of ongoing bleeding was present, or FIBTEM MCF was 10 mm or higher the patient was considered screen failure and excluded from further observation.

Forty patients were randomized to receive the assigned treatment.

Fibrinogen was administrated intravenously by infusion at a rate of approximately 20 ml/min. Ten minutes after fibrinogen administration a second test was performed with ROTEM® EXTEM and FIBTEM tests to record the change of the parameters due to fibrinogen supplementation. No other hemostatic drugs nor transfusions, outside the study drug, were administered between the first and the second testing. In case of ongoing intra- or postoperative bleeding, after the second testing, all the hemostatic corrections were allowed and guaranteed by our institutional protocol for postoperative bleeding management, which includes the following step-by-step interventions:

* 30-50 mg of additional protamine for the correction of residual heparin, if the CT at INTEM exceeded 20% of the CT at HEPTEM;
* Additional fibrinogen concentrate, if FIBTEM MCF \< 10 mm or Clauss fibrinogen \< 150 mg dL-1;
* Platelet concentrates if P2Y12 receptor inhibitors were discontinued not later than 7 days, a postoperative ADP test at Multiplate® aggregometry \< 12 U, or a postoperative platelet count measured or presumed from preoperative count \<100,000 cells/µL;
* 4-factors prothrombin complex concentrate (PCC, Pronativ, Octapharma, Lachen, Switzerland) 20 IU kg-1 if EXTEM CT \> 100 s (after correction of fibrinogen and platelet values) or INR \> 1,5.

Preoperative, and perioperative data and details of postoperative outcomes were retrieved from our institutional database and patients' medical charts, including demographics, preoperative risk factors, procedure details, postoperative bleeding and transfusions, intensive care unit (ICU), and hospital stay duration. For the study, the following additional data have been collected: preoperative fibrinogen, platelet count, coagulation parameters (prothrombin time, PT; international normalized ratio, INR; activated partial thromboplastin time, aPTT), post protamine EXTEM CT and MCF and FIBTEM MCF; post-fibrinogen supplementation EXTEM CT and MCF and FIBTEM MCF; fibrinogen, platelet count and coagulation at the ICU arrival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypofibrinogenemia Surgical Blood Loss Bleeding Cardiac Disease Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, double-blind, randomized

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

A computerized system generated a randomization sequence, and then sealed envelopes containing the drug assigned was prepared. The randomization ratio of the treatment arms was 1:1. An unblinded biologist (E.B.) was in charge of running the ROTEM® tests, randomization, drug preparation, and masking, and its delivery to the operating room. The attending anesthesiologist, the surgical staff, and the medical staff in the ICU and ward were blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FibCLOT

Patients randomized to the FibCLOT arm will receive 30 mg/kg, approximated to the closest between 2 and 3 grams, of FibCLOT (LFB, Puteaux, France).

Group Type EXPERIMENTAL

FibCLOT

Intervention Type DRUG

30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration

RiaSTAP

Patients randomized to the RiaSTAP arm will receive 30 mg/kg, approximated to the closest between 2 and 3 grams, of RiaSTAP (King of Prussia, PA, USA).

Group Type ACTIVE_COMPARATOR

RiaSTAP

Intervention Type DRUG

30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FibCLOT

30 mg/kg of FibCLOT (rounded up to the nearest 2 or 3 grams) after protamine administration

Intervention Type DRUG

RiaSTAP

30 mg/kg of RiaSTAP (rounded up to the nearest 2 or 3 grams) after protamine administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Human Fibrinogen concentrate Human Fibrinogen concentrate

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* elective cardiac surgery with cardiopulmonary bypass;
* complex cardiac surgery (coronary artery bypass graft + valve repair/replacement; double/triple valve repair/replacement; ascendant aorta surgery);
* written consent to participate;

Exclusion Criteria

* urgent or emergent cardiac surgery;
* known hypersensitivity to the active principle or to one of the excipients of the study drugs;
* coagulation disorders, known or presumable from anamnesis;
* known hepatopathy;
* known risk of thrombosis or disseminated intravascular coagulation;
* participation in another clinical study where an experimental product has been administered within 30 days from the day of the inclusion in the study;
* whatever clinical condition that, in the opinion of the investigator, makes the patients not suitable to the experimentation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No